https://scholars.lib.ntu.edu.tw/handle/123456789/582262
標題: | Global control of hepatitis B virus infection | 作者: | JIA-HORNG KAO DING-SHINN CHEN |
公開日期: | 2002 | 出版社: | Lancet Publishing Group | 卷: | 2 | 期: | 7 | 起(迄)頁: | 395-403 | 來源出版物: | Lancet Infectious Diseases | 摘要: | Worldwide about 350 million people are chronic carriers of the hepatitis B virus (HBV). The infection can cause acute and chronic liver disease including cirrhosis and hepatocellular carcinoma (HCC). Hepatocellular injuries of HBV infection are predominantly immune-mediated, and the natural history of chronic infection can be divided into three phases based on virus-host interactions-namely, immune tolerance, immune clearance, and viral integration phases. Four serotypes (adw, ayw, adr, and ayr) and seven genotypes (A to G) of HBV have been identified, and they show some distinct geographic distributions. The HBV genotypes may have clinical relevance and are currently under investigation. On the basis of disease burden and the availability of safe and effective vaccines, the WHO recommended that by the endq of the 20th century hepatitis B vaccine be incorporated into routine infant and childhood immunisation programmes for all countries. The efficacy of universal immunisation has been shown in different countries, with striking reductions of the prevalence of HBV carriage in children. Most important, hepatitis B vaccination can protect children against HCC and fulminant hepatitis, as has been shown in Taiwan. Nevertheless, the implementation of worldwide vaccination against HBV requires greater effort to overcome the social and economic hurdles. Safe and effective antiviral treatments are available but are still far from ideal, a situation that, hopefully, will be improved soon. With hepatitis B immunisation, the global control of HBV infection is possible by the end of the first half of 21st century. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036293243&doi=10.1016%2fS1473-3099%2802%2900315-8&partnerID=40&md5=b5e6d950dd6c43c57d49186ceca9ed7d https://scholars.lib.ntu.edu.tw/handle/123456789/582262 |
ISSN: | 1473-3099 | DOI: | 10.1016/S1473-3099(02)00315-8 | SDG/關鍵字: | hepatitis B vaccine; disease course; genotype; geographic distribution; hepatitis B; Hepatitis B virus; human; immunization; infection control; liver cell carcinoma; priority journal; review; vaccination; virus cell interaction; virus pathogenesis |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。